Companies

GSK

5 articles

Industry NewsGSKSTAT News

GSK wins FDA approval for its hepatitis B drug

  • STAT reports that GSK has won FDA approval for its hepatitis B drug.
  • The drug extended functional cures to far more patients than previous methods, according to the report.
  • Details beyond the headline were not available to us; the product is understood to be the antisense bepirovirsen.
PointsBased on public reports

A functional-cure label in hepatitis B is a landmark for the field, and GSK gets it with an antisense oligo, not a small molecule or antibody. The commercial question is uptake: finite treatment courses mean less recurring revenue per patient, but a large, long-diagnosed population. Watch Vir, Arbutus and the Chinese siRNA players, who now have a bar to clear.

Industry NewsGSK / Hansoh PharmaceuticalFierce Biotech

GSK Doubles Down on China-Sourced ADCs After Hansoh Deal Delivers Phase 3 Win

  • In 2023, GSK paid about $270 million upfront for ex-China rights to two Hansoh Pharma antibody-drug conjugates targeting B7-H3 and B7-H4.
  • The B7-H3 candidate has since posted an 18.5-month median overall-survival benefit in relapsed small-cell lung cancer, plus a progression-free-survival win in osteosarcoma.
  • GSK plans to push the B7-H4 asset into five additional Phase 3 trials, reinforcing a dual in-house/China-sourced oncology pipeline strategy.
PointsBased on public reports

The $270M upfront now looks like a steal — a Phase 3 survival win in SCLC plus a PFS hit in osteosarcoma would command a far richer price today, which is exactly why AstraZeneca, Merck and Pfizer scrambled to strike their own China ADC deals. Five more B7-H4 Phase 3s isn't optionality — it's GSK committing real capital to a China-sourced pipeline, not hedging it.

Industry NewsHUTCHMED / GSKEndpoints News

GSK licenses HUTCHMED's first-in-class KRAS-EGFR conjugate HMPL-A830 in deal worth up to $1.3B

  • HUTCHMED and a GSK subsidiary signed an exclusive development and license agreement for HMPL-A830, described as a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (ATTC).
  • HMPL-A830 pairs a highly selective, potent small-molecule KRAS inhibitor payload with an anti-EGFR antibody, delivering the inhibitor selectively to EGFR-expressing tumor cells while also blocking EGFR signaling.
  • GSK gains worldwide development and commercialization rights excluding Mainland China, Hong Kong, Macau and Taiwan, which HUTCHMED retains.
  • Deal terms: $110 million upfront, up to $1.295 billion in additional development, regulatory and commercial milestone payments, plus tiered royalties on net sales.
  • HUTCHMED will conduct the global Phase 1 program, expected to start in H2 2026, after which GSK takes over subsequent clinical development and commercialization.
  • Initial clinical development will focus on colorectal, pancreatic and lung cancers.
PointsBased on public reports

Another Western major fills its oncology pipeline via China-origination rather than in-house discovery — GSK joins a fast-growing queue of ADC/conjugate deals mining HUTCHMED's pipeline for de-risked-but-early assets. The math is telling: $110M upfront against a $1.295B ceiling is roughly 8.5% at signing — real conviction, heavily hedged, standard for a preclinical/Phase 1 asset where GSK is paying mostly for optionality until clinical data lands. The ATTC design — a small-molecule KRAS payload riding an EGFR antibody — is a genuinely differentiated angle in an overcrowded KRAS field, avoiding classic cytotoxic-ADC toxicity while adding tumor-selective targeting. And HUTCHMED keeping Greater China rights again signals its now-familiar playbook: license out ex-China, retain commercial control at home.

Industry NewsGSK / Chimagen BiosciencesEndpoints News

GSK Licenses Trispecific T-Cell Engager from Chimagen for Multiple Myeloma in Deal Worth Up to $750M

  • GSK has agreed to license a preclinical trispecific T-cell engager (TCE) from China-based Chimagen Biosciences for the treatment of multiple myeloma.
  • The agreement includes an upfront payment plus development and commercial milestones, with total potential deal value of up to $750 million.
  • Unlike currently approved bispecific TCEs in myeloma, the candidate binds T cells while simultaneously engaging two validated tumor-associated antigens, a design intended to improve efficacy and tolerability.
  • The program remains preclinical; GSK expects the asset to enter Phase I trials in 2027.
  • This is GSK's second licensing deal with Chimagen, following a 2024 agreement worth up to $850 million for a separate TCE targeting B-cell-mediated autoimmune disease.
PointsBased on public reports

Preclinical asset, real money: up to $750M for a molecule years from human data is a differentiation bet, not a de-risking buy — GSK is wagering the third binding arm clears a bar that Tecvayli, Talvey, and Elrexfio already set. Trispecific design is the pitch, but myeloma TCEs are now a crowded field; incremental antigen coverage has to translate into durability or safety gains, not just a cleaner mechanism story. Second Chimagen deal in under two years (after the $850M autoimmune TCE in 2024) turns a one-off license into a platform relationship — GSK is treating this China-based biotech's engineering as a recurring pipeline source, echoing the broader Western-pharma pivot to China for early oncology assets. Phase I isn't until 2027, so this is a multi-year credibility test for GSK's TCE bet across both oncology and autoimmune.

Industry NewsGSKFierce Biotech

GSK Advances Dual-Target mRNA Flu Vaccine to Phase 3 Trial

  • GSK will start a Phase 3 trial of its mRNA seasonal flu vaccine after Phase 2 data (Flu-028, ~971 adults) showed stronger immune responses against every tested flu strain than licensed comparator vaccines, with acceptable tolerability.
  • Unlike most approved flu shots, which target only hemagglutinin (HA), GSK's candidate also encodes neuraminidase (NA), the second major surface protein flu uses to spread between cells.
  • Growing evidence suggests adding an NA response could improve protection, reduce illness severity, and limit transmission compared with HA-only vaccines.
  • The Phase 3 trial will be the first late-stage study of a dual HA/NA mRNA flu vaccine, positioning GSK against Moderna's newly approved single-target mRNA flu shot.
  • The FDA granted the candidate Fast Track designation in July 2026, and GSK expects to begin the pivotal trial this month.
PointsBased on public reports

GSK's bet: that the stronger immune responses seen in Phase 2 translate into real clinical benefit — fewer infections, milder illness, less transmission — which an HA-only shot like Moderna's already-approved mRNA flu vaccine can't match. This is the first real Phase 3 test of the "NA matters" thesis, not yet proven at scale. It's a platform signal as much as a product one. After lagging Pfizer/Moderna's first-generation, single-antigen mRNA vaccines, a Phase 3 win would show GSK's mRNA engine can handle more complex, multi-antigen constructs. Flu vaccines are a large but seasonal, commoditized, price-pressured market — the real payoff isn't flu revenue itself, it's flu as the proving ground before GSK extends dual/multi-antigen mRNA into RSV, combo respiratory shots, or pandemic-response platforms. If it works, expect the mRNA flu narrative to shift from "mRNA vs. egg-based" to "how many antigens can you stack" — the next competitive axis in a race that's outgrowing its first generation.